Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study

Francesca Sofia Di Lisa¹, Eriseld Krasniqi², Laura Pizzuti², Maddalena Barba², Katia Cannita³, Ugo De Giorgi⁴, Fulvio Borella⁵, Jennifer Foglietta⁶, Anna Cariello⁷, Antonella Ferro⁸, Elisa Picardo⁹, Marco Mitidieri⁹, Valentina Sini¹⁰, Simonetta Stani¹⁰, Giuseppe Tonini¹¹, Daniele Santini¹², Nicla La Verde¹³, Anna Rita Gambaro¹³, Antonino Grassadonia¹⁴, Nicola Tinari¹⁵, Ornella Garrone¹⁶, Giuseppina Sarobba¹⁷, Lorenzo Livi^{18

19}, Icro Meattini^{18

19}, Giuliana D'Auria²⁰, Matteo Vergati²⁰, Teresa Gamucci²⁰, Mirco Pistelli²¹, Rossana Berardi²¹, Emanuela Risi²², Francesco Giotta²³, Vito Lorusso²³, Lucia Rinaldi²⁴, Salvatore Artale²⁵, Marina Elena Cazzaniga^{26

27}, Fable Zustovich²⁸, Federico Cappuzzo², Lorenza Landi²⁹, Rosalba Torrisi³⁰, Simone Scagnoli³¹, Andrea Botticelli¹², Andrea Michelotti³², Beatrice Fratini³², Rosa Saltarelli³³, Ida Paris³⁴, Margherita Muratore³⁴, Alessandra Cassano³⁵, Lorenzo Gianni³⁶, Valeria Gaspari³⁶, Enzo Maria Veltri³⁷, Federica Zoratto³⁷, Elena Fiorio³⁸, Maria Agnese Fabbri³⁹, Marco Mazzotta³⁹, Enzo Maria Ruggeri³⁹, Rebecca Pedersini⁴⁰, Maria Rosaria Valerio⁴¹, Lorena Filomeno¹, Mauro Minelli⁴², Paola Scavina⁴², Mimma Raffaele⁴³, Antonio Astone⁴⁴, Roy De Vita⁴⁵, Marcello Pozzi⁴⁵, Ferdinando Riccardi⁴⁶, Filippo Greco⁴⁷, Luca Moscetti⁴⁸, Monica Giordano⁴⁹, Marcello Maugeri-Saccà^{2

50}, Alessandro Zennaro⁵⁰, Claudio Botti⁵¹, Fabio Pelle⁵¹, Sonia Cappelli⁵¹, Flavia Cavicchi⁵¹, Enrico Vizza⁵², Giuseppe Sanguineti⁵³, Federica Tomao⁵⁴, Enrico Cortesi⁵⁵, Paolo Marchetti⁵⁶, Silverio Tomao⁵⁷, Iolanda Speranza¹², Isabella Sperduti⁵⁰, Gennaro Ciliberto⁵⁸, Patrizia Vici¹

Affiliations

¹ Phase IV Clinical Studies Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
² Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
³ Oncology Division, Mazzini Hospital, ASL Teramo, Teramo, Italy.
⁴ Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
⁵ Gynecology and Obstetrics 1, Department of Surgical Sciences, City of Health and Science, Sant' Anna Hospital, University of Turin, Turin, Italy.
⁶ Medical Oncology, P.O. Narni-Amelia, Terni, Italy.
⁷ Oncology Department, AUSL Romagna, Ravenna, Italy.
⁸ Breast Center, Santa Chiara Hospital, Trento, Italy.
⁹ Gynecology and Obstetrics 4, Department of Surgical Sciences, City of Health and Science, Sant' Anna Hospital, University of Turin, Turin, Italy.
¹⁰ Medical Oncology, Santo Spirito Hospital, Rome, Italy.
¹¹ Department of Medical Oncology, Fondazione Policlinico Universitario Campus Biomedico, Rome, Italy.
¹² Medical Oncology A, Policlinico Umberto I, Department of Radiological, Oncological and Anatomo-Pathological Sciences, "Sapienza" University of Rome, Rome, Italy.
¹³ Department of Oncology, Ospedale Luigi Sacco, ASST Fatebenefratelli Sacco, Milan, Italy.
¹⁴ Department of Innovative Technologies in Medicine and Dentistry and Centre for Advanced Studies and Technology (CAST), G. D'Annunzio University, Chieti, Italy.
¹⁵ Department of Medical, Oral and Biotechnological Sciences and Center for Advanced Studies and Technology (CAST), G. D'Annunzio University, Chieti, Italy.
¹⁶ Medical Oncology, Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico Milano, Milan, Italy.
¹⁷ Department of Medical Oncology, ASL Nuoro, Nuoro, Italy.
¹⁸ Department of Biomedical, Experimental and Clinical Sciences "M. Serio", University of Florence, Florence, Italy.
¹⁹ Radiotherapy Unit, Oncology Department, Azienda Ospedaliera Universitaria Careggi, Florence, Italy.
²⁰ UOC of Medical Oncology, Sandro Pertini Hospital, Rome, Italy.
²¹ Oncology Clinic, Università Politecnica delle Marche, Ospedali Riuniti Hospital, Ancona, Italy.
²² Sandro Pitigliani Medical Oncology Department, Hospital of Prato, Prato, Italy.
²³ Department of Medical Oncology, IRCCS Giovanni Paolo II Institute, Bari, Italy.
²⁴ "Don Tonino Bello" Oncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
²⁵ Oncology Department, Ospedale di Gallarate, ASST Valle Olona, Gallarate, Italy.
²⁶ Phase 1 Research Centre and Oncology Unit, Department of Medicine and Surgery, University of Milano-Bicocca, ASST Monza, Monza, Italy.
²⁷ Oncology Unit, ASST Monza, Monza, Italy.
²⁸ Oncology Division, AULSS 1 Dolomiti, San Martino Medical Hospital, Belluno, Italy.
²⁹ Phase I Clinical Studies Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
³⁰ Department of Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Milan, Italy.
³¹ Department of Medical and Surgical Sciences and Translational Medicine, "Sapienza" University of Rome, Rome, Italy.
³² UO Medical Oncology I, S. Chiara Hospital, Pisa University Hospital, Pisa, Italy.
³³ Oncology Division, San Giovanni Evangelista Hospital, ASL RM5, Rome, Italy.
³⁴ Division of Gynecologic Oncology, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
³⁵ Medical Oncology, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.
³⁶ Oncology Unit Rimini, Azienda USL Romagna, Rimini, Italy.
³⁷ Medical Oncology Unit, Santa Maria Goretti Hospital, Latina, Italy.
³⁸ Pathology Unit, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
³⁹ Medical Oncology Unit, Belcolle Hospital, Viterbo, Italy.
⁴⁰ Breast Unit-Oncologia, ASST-Spedali Civili, Brescia, Italy.
⁴¹ Medical Oncology, Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone, Palermo, Italy.
⁴² Division of Oncology, San Giovanni Hospital, Rome, Italy.
⁴³ Presidio Oncologico Cassia - S. Andrea, ASL Roma 1, Rome, Italy.
⁴⁴ Oncology Division, San Pietro Fatebenefratelli Hospital, Rome, Italy.
⁴⁵ Department of Plastic and Reconstructive Surgery, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
⁴⁶ Oncology Unit, Antonio Cardarelli Hospital, Naples, Italy.
⁴⁷ Medical Oncology Unit, AULSS 9 Regione Veneto, Scaligera - Ospedale Generale Mater Salutis, Legnago, Italy.
⁴⁸ Division of Medical Oncology, Department of Oncology-Hematology, University Hospital of Modena, Modena, Italy.
⁴⁹ Medical Oncology Division, ASST-Lariana, Como, Italy.
⁵⁰ Clinical Trial Center, Biostatistics and Bioinformatics, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
⁵¹ Department of Surgery, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
⁵² Gynecologic Oncology Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
⁵³ Department of Radiation Oncology, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
⁵⁴ Department of Maternal and Child Health and Urological Sciences, "Sapienza" University of Rome, Policlinico Umberto I, Rome, Italy.
⁵⁵ Medical Oncology B, Policlinico Umberto I, Department of Radiological, Oncological and Pathological Sciences, "Sapienza" University of Rome, Rome, Italy.
⁵⁶ Scientific Direction, IRCCS IDI, Istituto Dermopatico dell'Immacolata, Rome, Italy.
⁵⁷ Department of Radiological, Oncological and Pathological Sciences, "Sapienza" University of Rome, Rome, Italy.
⁵⁸ Scientific Direction, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

PMID: 37260975
PMCID: PMC10227592
DOI: 10.3389/fonc.2023.1152123

Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study

Francesca Sofia Di Lisa et al. Front Oncol. 2023.

. 2023 May 16:13:1152123.

doi: 10.3389/fonc.2023.1152123. eCollection 2023.

Authors

Affiliations

¹ Phase IV Clinical Studies Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
² Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
³ Oncology Division, Mazzini Hospital, ASL Teramo, Teramo, Italy.
⁴ Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
⁵ Gynecology and Obstetrics 1, Department of Surgical Sciences, City of Health and Science, Sant' Anna Hospital, University of Turin, Turin, Italy.
⁶ Medical Oncology, P.O. Narni-Amelia, Terni, Italy.
⁷ Oncology Department, AUSL Romagna, Ravenna, Italy.
⁸ Breast Center, Santa Chiara Hospital, Trento, Italy.
⁹ Gynecology and Obstetrics 4, Department of Surgical Sciences, City of Health and Science, Sant' Anna Hospital, University of Turin, Turin, Italy.
¹⁰ Medical Oncology, Santo Spirito Hospital, Rome, Italy.
¹¹ Department of Medical Oncology, Fondazione Policlinico Universitario Campus Biomedico, Rome, Italy.
¹² Medical Oncology A, Policlinico Umberto I, Department of Radiological, Oncological and Anatomo-Pathological Sciences, "Sapienza" University of Rome, Rome, Italy.
¹³ Department of Oncology, Ospedale Luigi Sacco, ASST Fatebenefratelli Sacco, Milan, Italy.
¹⁴ Department of Innovative Technologies in Medicine and Dentistry and Centre for Advanced Studies and Technology (CAST), G. D'Annunzio University, Chieti, Italy.
¹⁵ Department of Medical, Oral and Biotechnological Sciences and Center for Advanced Studies and Technology (CAST), G. D'Annunzio University, Chieti, Italy.
¹⁶ Medical Oncology, Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico Milano, Milan, Italy.
¹⁷ Department of Medical Oncology, ASL Nuoro, Nuoro, Italy.
¹⁸ Department of Biomedical, Experimental and Clinical Sciences "M. Serio", University of Florence, Florence, Italy.
¹⁹ Radiotherapy Unit, Oncology Department, Azienda Ospedaliera Universitaria Careggi, Florence, Italy.
²⁰ UOC of Medical Oncology, Sandro Pertini Hospital, Rome, Italy.
²¹ Oncology Clinic, Università Politecnica delle Marche, Ospedali Riuniti Hospital, Ancona, Italy.
²² Sandro Pitigliani Medical Oncology Department, Hospital of Prato, Prato, Italy.
²³ Department of Medical Oncology, IRCCS Giovanni Paolo II Institute, Bari, Italy.
²⁴ "Don Tonino Bello" Oncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
²⁵ Oncology Department, Ospedale di Gallarate, ASST Valle Olona, Gallarate, Italy.
²⁶ Phase 1 Research Centre and Oncology Unit, Department of Medicine and Surgery, University of Milano-Bicocca, ASST Monza, Monza, Italy.
²⁷ Oncology Unit, ASST Monza, Monza, Italy.
²⁸ Oncology Division, AULSS 1 Dolomiti, San Martino Medical Hospital, Belluno, Italy.
²⁹ Phase I Clinical Studies Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
³⁰ Department of Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Milan, Italy.
³¹ Department of Medical and Surgical Sciences and Translational Medicine, "Sapienza" University of Rome, Rome, Italy.
³² UO Medical Oncology I, S. Chiara Hospital, Pisa University Hospital, Pisa, Italy.
³³ Oncology Division, San Giovanni Evangelista Hospital, ASL RM5, Rome, Italy.
³⁴ Division of Gynecologic Oncology, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
³⁵ Medical Oncology, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.
³⁶ Oncology Unit Rimini, Azienda USL Romagna, Rimini, Italy.
³⁷ Medical Oncology Unit, Santa Maria Goretti Hospital, Latina, Italy.
³⁸ Pathology Unit, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
³⁹ Medical Oncology Unit, Belcolle Hospital, Viterbo, Italy.
⁴⁰ Breast Unit-Oncologia, ASST-Spedali Civili, Brescia, Italy.
⁴¹ Medical Oncology, Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone, Palermo, Italy.
⁴² Division of Oncology, San Giovanni Hospital, Rome, Italy.
⁴³ Presidio Oncologico Cassia - S. Andrea, ASL Roma 1, Rome, Italy.
⁴⁴ Oncology Division, San Pietro Fatebenefratelli Hospital, Rome, Italy.
⁴⁵ Department of Plastic and Reconstructive Surgery, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
⁴⁶ Oncology Unit, Antonio Cardarelli Hospital, Naples, Italy.
⁴⁷ Medical Oncology Unit, AULSS 9 Regione Veneto, Scaligera - Ospedale Generale Mater Salutis, Legnago, Italy.
⁴⁸ Division of Medical Oncology, Department of Oncology-Hematology, University Hospital of Modena, Modena, Italy.
⁴⁹ Medical Oncology Division, ASST-Lariana, Como, Italy.
⁵⁰ Clinical Trial Center, Biostatistics and Bioinformatics, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
⁵¹ Department of Surgery, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
⁵² Gynecologic Oncology Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
⁵³ Department of Radiation Oncology, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
⁵⁴ Department of Maternal and Child Health and Urological Sciences, "Sapienza" University of Rome, Policlinico Umberto I, Rome, Italy.
⁵⁵ Medical Oncology B, Policlinico Umberto I, Department of Radiological, Oncological and Pathological Sciences, "Sapienza" University of Rome, Rome, Italy.
⁵⁶ Scientific Direction, IRCCS IDI, Istituto Dermopatico dell'Immacolata, Rome, Italy.
⁵⁷ Department of Radiological, Oncological and Pathological Sciences, "Sapienza" University of Rome, Rome, Italy.
⁵⁸ Scientific Direction, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

PMID: 37260975
PMCID: PMC10227592
DOI: 10.3389/fonc.2023.1152123

Abstract

Background: In triple negative breast cancer patients treated with neoadjuvant chemotherapy, residual disease at surgery is the most relevant unfavorable prognostic factor. Current guidelines consider the use of adjuvant capecitabine, based on the results of the randomized CREATE-X study, carried out in Asian patients and including a small subset of triple negative tumors. Thus far, evidence on Caucasian patients is limited, and no real-world data are available.

Methods: We carried out a multicenter, observational study, involving 44 oncologic centres. Triple negative breast cancer patients with residual disease, treated with adjuvant capecitabine from January 2017 through June 2021, were recruited. We primarily focused on treatment tolerability, with toxicity being reported as potential cause of treatment discontinuation. Secondarily, we assessed effectiveness in the overall study population and in a subset having a minimum follow-up of 2 years.

Results: Overall, 270 patients were retrospectively identified. The 50.4% of the patients had residual node positive disease, 7.8% and 81.9% had large or G3 residual tumor, respectively, and 80.4% a Ki-67 >20%. Toxicity-related treatment discontinuation was observed only in 10.4% of the patients. In the whole population, at a median follow-up of 15 months, 2-year disease-free survival was 62%, 2 and 3-year overall survival 84.0% and 76.2%, respectively. In 129 patients with a median follow-up of 25 months, 2-year disease-free survival was 43.4%, 2 and 3-year overall survival 78.0% and 70.8%, respectively. Six or more cycles of capecitabine were associated with more favourable outcomes compared with less than six cycles.

Conclusion: The CaRe study shows an unexpectedly good tolerance of adjuvant capecitabine in a real-world setting, although effectiveness appears to be lower than that observed in the CREATE-X study. Methodological differences between the two studies impose significant limits to comparability concerning effectiveness, and strongly invite further research.

Keywords: adjuvant capecitabine; neoadjuvant treatment; residual tumors; treatment discontinuation; triple negative breast cancer.

Copyright © 2023 Di Lisa, Krasniqi, Pizzuti, Barba, Cannita, De Giorgi, Borella, Foglietta, Cariello, Ferro, Picardo, Mitidieri, Sini, Stani, Tonini, Santini, La Verde, Gambaro, Grassadonia, Tinari, Garrone, Sarobba, Livi, Meattini, D’Auria, Vergati, Gamucci, Pistelli, Berardi, Risi, Giotta, Lorusso, Rinaldi, Artale, Cazzaniga, Zustovich, Cappuzzo, Landi, Torrisi, Scagnoli, Botticelli, Michelotti, Fratini, Saltarelli, Paris, Muratore, Cassano, Gianni, Gaspari, Veltri, Zoratto, Fiorio, Fabbri, Mazzotta, Ruggeri, Pedersini, Valerio, Filomeno, Minelli, Scavina, Raffaele, Astone, De Vita, Pozzi, Riccardi, Greco, Moscetti, Giordano, Maugeri-Saccà, Zennaro, Botti, Pelle, Cappelli, Cavicchi, Vizza, Sanguineti, Tomao, Cortesi, Marchetti, Tomao, Speranza, Sperduti, Ciliberto and Vici.

PubMed Disclaimer

Conflict of interest statement

LP received speaker fees from Novartis, outside the submitted work. UDG: Pfizer, BMS, MSD, PharmaMAR, AStellas, Bayer, Ipsen, Novartis; Invited speaker Roche, BMS, SAnofi, AstraZeneca; received research grants from AstraZeneca, SAnofi, Roche, outside the submitted work. AF received honoraria as a speaker from Eli Lilly, Novartis, Pierre-Fabre, outside the submitted work. GT: advisory boards from Novartis, Pfizer, Eisai, Roche, and Eli Lilly, outside the submitted work. DS: advisory boards from Novartis, Pfizer, Eisai, Roche, and Eli Lilly, outside the submitted work. NLV: Roche, MSD, Eisai, Novartis, AstraZeneca, GSK, Pfizer, Gentili, Daiichi Sankyo, Dephaforum, outside the submitted work. OG: Eisai, MSD, Gilead, Seagen, Novartis, Eli Lilly, outside the submitted work. IM: advisory boards from Eli Lilly, Novartis, Gentili, Roche, Pfizer, Ipsen, and Pierre-Fabre, outside the submitted work. GD’A: Novartis, Amgen, Eli Lilly outside the submitted work. TG received travel grants from Eisai, Roche, Pfizer, and Novartis; speaker fees/advisory boards from Roche, Pfizer, Novartis, Gentili, and Eli Lilly, outside the submitted work. MPi Consultant/advisory boards from Gilead, Eli Lilly, Pfizer, Novartis, Gentili, MSD, outside the submitted work. RB received research grant/advisory boards from AstraZeneca, Boehringer Ingelheim, Novartis, MSD, Otsuka, Eli Lilly, Roche, Amgen, GSK, Eisai, outside the submitted work. FGi: advisory boards from Gilead, Daiichi Sankyo, Seagen, outside the submitted work. MEC consultant/advisory role for Pierre-Fabre, Roche, Novartis, Eli Lilly, Celgene, outside the submitted work. RT: AstraZeneca, Eisai, Pfizer, Eli Lilly, MSD, Exact Science, outside the submitted work. AB: MSD, BMS, Pfizer, Novartis, Roche outside the submitted work. AM received travel grants from Eisai, Celgene, and Novartis Ipsen; personal fees/advisory boards from Eisai, Novartis, AstraZeneca, Teva, Pfizer, and Celgene, outside the submitted work. IP received personal fees/advisory boards from Roche, Pfizer, Novartis, Italfarmaco, Gentili, and Pierre-Fabre. LG received congress travel accomodation from Roche, Daiichi Sankyo, AstraZeneca, Pfizer, Novartis; advisory role for Astra Zeneca outside the submitted work. MMin: Novartis, MSD, Eli Lilly, outside the submitted work. LM received personal fees/advisory board from Roche, Novartis, Eisai, and Pfizer, outside the submitted work. EC: Astellas, Roche, BMS, Jansen, MSD, Sirtex, Merck, Bayer, Servier, Novartis, outside the submitted work. PM has/had a consultant/advisory role for BMS, Roche, Genentech, MSD, Novartis, Amgen, Merck Serono, Pierre-Fabre and Incyte, outside the submitted work. PV received speaker fees/advisory boards from Roche, Pfizer, Novartis and Eli Lilly, outside the submitted work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

**Figure 1**
Disease free survival by nodal status **(A)**, grading **(B)**, Ki67 **(C)**, residual breast disease **(D)**, breast surgery **(E)** and axillary surgery **(F)** in 270 patients.

**Figure 2**
Disease free survival by nodal status **(A)**, grading **(B)**, Ki67 **(C)**, residual breast disease **(D)**, breast surgery **(E)** and axillary surgery **(F)** in 129 patients.

**Figure 3**
Overall survival by nodal status **(A)**, grading **(B)**, Ki67 **(C)**, residual breast disease **(D)**, breast surgery **(E)** and axillary surgery **(F)** in 270 patients.

**Figure 4**
Overall survival by nodal status **(A)**, grading **(B)**, Ki67 **(C)**, residual breast disease **(D)**, breast surgery **(E)** and axillary surgery **(F)** in 129 patients.

See this image and copyright information in PMC

References

1. Dawson SJ, Provenzano E, Caldas C. Triple negative breast cancers: clinical and prognostic implications. Eur J Cancer (2009) 45:27–40. doi: 10.1016/S0959-8049(09)70013-9 - DOI - PubMed
1. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, et al. . The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res (2007) 13(8):2329–34. doi: 10.1158/1078-0432.CCR-06-1109 - DOI - PubMed
1. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. . Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res (2007) 13(15 Pt 1):4429–34. doi: 10.1158/1078-0432.CCR-06-3045 - DOI - PubMed
1. Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA. Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat (2009) 115(2):423–8. doi: 10.1007/s10549-008-0086-2 - DOI - PubMed
1. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. . Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet (2014) 384(9938):164–72. doi: 10.1016/S0140-6736(13)62422-8 - DOI - PubMed

LinkOut - more resources

Full Text Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study

Affiliations

Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

References

LinkOut - more resources

Full Text Sources